Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
Farmers Insurance
Boehringer Ingelheim
Harvard Business School
Cantor Fitzgerald
Colorcon
Queensland Health
US Department of Justice
Mallinckrodt

Generated: December 12, 2017

DrugPatentWatch Database Preview

CEPHULAC Drug Profile

« Back to Dashboard

When do Cephulac patents expire, and what generic alternatives are available?

Cephulac is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in CEPHULAC is lactulose. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the lactulose profile page.
Drug patent expirations by year for CEPHULAC

Medical Subject Heading (MeSH) Categories for CEPHULAC

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsCEPHULAClactuloseSOLUTION;ORAL, RECTAL017657-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CEPHULAC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis UsCEPHULAClactuloseSOLUTION;ORAL, RECTAL017657-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsCEPHULAClactuloseSOLUTION;ORAL, RECTAL017657-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsCEPHULAClactuloseSOLUTION;ORAL, RECTAL017657-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsCEPHULAClactuloseSOLUTION;ORAL, RECTAL017657-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsCEPHULAClactuloseSOLUTION;ORAL, RECTAL017657-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsCEPHULAClactuloseSOLUTION;ORAL, RECTAL017657-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Merck
Citi
McKinsey
Medtronic
Argus Health
Fish and Richardson
Queensland Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot